Marker Therapeutics has launched the Phase 1 RAPID study to explore Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product for faster treatment. The OTS product was well tolerated, with safety data consistent with other MAR-T cell studies. The first patient has been treated in the OTS program, showing encouraging preliminary safety data. The therapy is aimed at patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) initially, with potential expansion to other indications. The OTS program aims to provide a quick treatment option for patients with aggressive diseases, with a potential turnaround time of 72 hours.

Marker Therapeutics’ OTS program has received non-dilutive funding from the FDA, NIH, and CPRIT to support clinical investigations. The Company has established a cellular inventory from commercially available leukapheresis material to cover a large patient population. The Phase 1 RAPID trial will provide valuable data to guide the future development of MAR-T cell products as an OTS option in various indications. The MAR-T cell platform allows the recognition of multiple tumor antigens, potentially reducing the risk of tumor escape, and offering a cost-effective and safer alternative to current T cell therapies.

Marker Therapeutics is a clinical-stage immuno-oncology company focused on T cell-based immunotherapies for hematological malignancies and solid tumors. The Company’s unique T cell platform has shown promising results in clinical trials, with a focus on operational excellence and financial resource preservation. Forward-looking statements indicate the Company’s commitment to advancing research and development efforts for potential future therapies. For more information, visit Marker Therapeutics’ website or contact investor relations for inquiries.

Read more at GlobeNewswire: Marker Therapeutics Announces First Patient Treated in